season
pandem
influenza
vaccin
tradit
made
inactiv
viru
grown
embryon
egg
howev
approach
sever
limit
includ
manufactur
delay
vaccin
seed
virus
eggadapt
insecur
egg
suppli
potenti
suppli
disrupt
pandem
viru
also
infect
chicken
flock
eggbas
vaccin
may
also
suitabl
individu
sever
egg
despit
recent
develop
largescal
facil
mammalian
cell
cultur
influenza
remain
suscept
delay
seed
virus
suitabl
cell
cultur
gener
screen
predict
speed
recombin
protein
manufactur
major
advantag
vaccin
product
potenti
reliabl
approach
pandem
vaccin
product
therefor
use
recombin
hemagglutinin
rha
protect
neutralis
antibodi
ha
seen
influenza
infect
us
govern
award
contract
rang
vaccin
compani
includ
protein
scienc
corpor
psc
medicago
novovax
fraunhof
institut
vaxinn
produc
recombin
influenza
vaccin
use
variou
psc
pioneer
use
baculoviru
express
system
produc
influenza
vaccin
base
rha
licens
fda
season
influenza
protect
pandem
variant
rha
vaccin
known
panblok
protect
bird
lethal
low
level
seroprotect
obtain
human
subject
indic
need
mani
adjuv
describ
progress
formul
licens
human
novel
polysaccharid
adjuv
base
particl
semicrystallin
delta
inulin
develop
support
us
nation
institut
health
adjuv
develop
anim
model
adjuv
shown
enhanc
immunogen
vaccin
wide
rang
diseas
includ
hepat
sar
japanes
west
nile
pest
de
petit
although
mechan
action
yet
fulli
determin
advax
particl
bind
directli
human
monocyt
enhanc
costimulatori
pandem
influenza
studi
ferret
model
advax
significantli
enhanc
protect
afford
inactiv
vaccin
provid
surviv
versu
surviv
seen
standard
vaccin
vaccin
advax
adjuv
provid
antigen
dosespar
significantli
reduc
neurolog
diseas
viral
shed
notabl
advax
shown
safe
immuneenhanc
human
formul
hepat
season
vaccin
influenza
pandem
caus
sudden
emerg
north
america
strain
origin
refer
swine
flu
provid
reallif
opportun
test
novel
pandem
vaccin
approach
first
detect
north
america
april
spread
rapidli
around
world
lead
declar
world
health
organ
global
pandem
june
new
influenza
viru
least
contagi
season
influenza
spread
quickli
particularli
among
younger
peopl
degre
preexist
immun
seen
older
adult
especi
age
possibl
due
previou
exposur
antigen
relat
influenza
virus
recent
season
influenza
vaccin
provid
minim
protect
novel
pandem
pandem
sever
initi
fear
caus
upsurg
hospit
intens
care
unit
admiss
sever
respiratori
ill
hypoxemia
multiorgan
failur
requir
ventil
given
need
rapid
develop
pandem
vaccin
varieti
approach
utilis
involv
inactiv
live
attenu
vaccin
use
altern
approach
develop
vaccin
use
recombin
hemagglutinin
combin
advax
delta
inulin
adjuv
vaccin
describ
novel
insight
obtain
process
develop
move
rapidli
possibl
human
clinic
trial
lesson
learn
could
bear
optim
vaccin
develop
futur
pandem
follow
onset
pandem
vaccin
reli
cultiv
adapt
influenza
viru
egg
took
month
establish
influenza
vaccin
seed
strain
initi
distribut
center
diseas
control
prevent
cdc
sourc
cdc
id
number
passag
mdck
cell
although
strain
subsequ
provid
unsatisfactori
egg
product
yield
delay
vaccin
manufactur
altern
higheryield
strain
identifi
psc
alreadi
clone
ha
viru
rna
templat
use
revers
transcriptas
pcr
reaction
rtpcr
gener
cdna
clone
baculoviru
transfer
vector
use
transfect
spodoptera
frugiperda
expr
sf
insect
cell
use
calcium
phosphat
precipit
linear
autographa
californica
multicapsid
nucleopolyhedroviru
acmnpv
clone
sequenc
compar
sequenc
publish
cdc
ha
sequenc
perfect
match
found
situat
uncommon
initi
clone
season
influenza
strain
sever
clone
prolin
posit
domain
variant
also
appear
virus
supplementari
figur
posit
domain
map
near
distal
tip
involv
receptor
bind
accord
predict
ha
crystal
structur
supplementari
figur
ensur
consist
cdc
publish
sequenc
acc
serin
posit
site
direct
mutagenesi
perform
baculoviru
clone
chang
rha
protein
variant
manufactur
behavior
could
studi
hemagglutin
activ
assay
perform
fresh
chicken
swine
red
blood
cell
rbc
chicken
rbc
undilut
rha
monoval
bulk
hemagglutin
titer
equival
ha
protein
indic
except
low
agglutin
activ
comparison
control
rha
haemagglutin
titer
equival
ha
protein
rhasimilarli
agglutin
activ
guinea
pig
rbc
trypsinis
rha
effect
lack
agglutin
activ
interestingli
contrast
rha
origin
rha
high
agglutin
activ
time
pandem
declar
minim
inform
avail
new
pandem
viru
help
inform
vaccin
design
typic
situat
new
pandem
strain
laboratori
character
particular
structur
determin
key
viral
receptor
protein
take
consider
time
indic
need
better
method
rapidli
character
novel
pandem
virus
group
previous
use
silico
structur
model
approach
rapidli
build
model
molecul
interest
includ
ha
novel
influenza
permit
rapid
analysi
viru
behavior
advanc
wetlaboratori
character
better
understand
unusu
behavior
viru
particular
differ
behavior
vs
rha
gener
homolog
model
ha
use
model
homolog
model
program
use
crystal
structur
earlier
ha
protein
templat
use
conduct
receptor
bind
analysi
use
molecular
dock
program
autodock
vina
bind
energi
vs
rha
calcul
avian
human
sialic
acid
receptor
bind
studi
confirm
substitut
signific
impact
predict
bind
conform
ha
head
region
avian
human
sialic
acid
receptor
fig
top
panel
predict
bind
energi
ha
variant
human
avian
sialic
acid
receptor
lower
bind
energi
ha
tabl
could
help
explain
lack
rbc
agglutin
activ
rha
variant
model
show
ha
mutat
alter
bind
mode
ha
head
sialic
acid
receptor
allow
format
hbond
sialic
acid
caus
receptor
molecul
move
toward
helix
lose
contact
fig
bottom
panel
sinc
locat
form
base
pocket
hbond
sialic
acid
prevent
receptor
contact
base
bind
pocket
interact
may
caus
ha
bind
receptor
reduc
affin
furthermor
sinc
receptor
enter
deep
bind
pocket
entri
water
hydrat
potenti
contact
site
reduc
stabil
interact
contrast
lose
hbond
abil
posit
sialic
acid
result
receptor
form
hbond
base
pocket
furthermor
sinc
receptor
capabl
enter
deep
pocket
potenti
hydrat
hbond
site
avoid
may
result
stabl
bind
ha
receptor
given
inabl
induc
agglutin
activ
vitro
vivo
studi
consid
necessari
identifi
whether
antigen
would
induc
neutralis
antibodi
could
protect
infect
vaccin
test
immunogen
mice
alon
advax
adjuv
despit
rha
antigen
agglutin
activ
vitro
use
immunis
mice
still
induc
antibodi
fig
abl
neutralis
agglutin
activ
rha
variant
retain
agglutin
activ
well
agglutin
activ
local
pandem
viru
isol
name
strain
character
viru
isol
patient
admit
flinder
medic
center
south
australia
acut
influenza
infect
isol
propag
mdck
cell
ha
gene
sequenc
confirm
match
publish
sequenc
immun
sera
rha
immun
mice
also
abl
neutralis
ha
activ
commerci
inactiv
vaccin
csl
australia
notabl
addit
advax
adjuv
rha
result
signific
increas
antiinfluenza
serum
level
immunis
mice
suggest
although
agglutin
activ
rha
could
still
induc
antibodi
abl
neutral
agglutin
activ
wildtyp
virus
given
speed
pandem
need
rapid
vaccin
manufactur
major
challeng
clinic
trial
identifi
suitabl
ha
antigen
use
hi
assay
design
would
prefer
use
rha
vaccin
antigen
assay
refer
rha
antigen
describ
agglutin
activ
either
chicken
guinea
pig
rbc
surprisingli
variant
rha
sequenc
produc
initi
baculoviru
clone
contain
receptorbind
site
potent
rbc
agglutin
activ
assess
suitabl
use
antigen
hi
assay
test
rha
recognit
refer
ferret
hyperimmun
sera
bei
nih
rha
gave
correct
ha
titer
indic
contain
equival
agglutin
epitop
wild
type
viru
monoval
inactiv
vaccin
panvax
csl
australia
becam
avail
also
use
conduct
hi
assay
parallel
rha
antigen
hi
titr
measur
hi
assay
use
guinea
pig
rbc
describ
studi
baselin
use
antigen
hi
assay
studi
subject
hi
titr
suggest
low
level
preexist
immun
south
australian
popul
time
studi
commenc
previous
report
hi
assay
result
highli
depend
actual
ha
antigen
well
speci
rbc
use
make
intern
standardis
assay
problemat
high
interassay
variabl
may
help
explain
markedli
differ
baselin
estim
seroprotect
report
variou
laboratori
around
world
inde
obtain
differ
estim
baselin
seroprotect
rate
studi
popul
depend
ha
antigen
use
hi
assay
lowest
baselin
seroprotect
estim
hi
assay
obtain
use
antigen
inactiv
grown
egg
highest
estim
obtain
use
rha
data
shown
importantli
differ
ha
antigen
provid
differ
estim
baselin
seroprotect
foldchang
pre
postimmunis
hi
titer
studi
subject
highli
correl
differ
ha
antigen
data
shown
given
differ
hi
result
obtain
use
differ
ha
antigen
report
studi
use
viru
three
week
singl
rha
immun
highest
respond
younger
subject
receiv
highest
rha
dose
togeth
advax
adjuv
seroprotect
rate
antigen
hi
assay
given
difficulti
compar
hi
assay
result
studi
compar
result
studi
convalesc
sera
hospit
patient
recov
confirm
subject
receiv
advax
adjuv
compar
higher
hi
titr
patient
recov
microneutr
mnt
assay
test
abil
immun
sera
prevent
live
influenza
viru
infect
cell
line
vitro
therebi
measur
broader
array
neutralis
antibodi
hi
assay
measur
abil
block
bind
ha
sialic
acid
addit
hi
activ
mnt
assay
detect
antibodi
block
vital
viru
function
includ
fusion
nucleic
acid
hi
mnt
result
compar
baselin
post
second
immunis
group
receiv
without
advax
adjuv
baselin
sampl
low
undetect
hi
titr
although
mani
posit
mnt
assay
indic
hi
assay
lower
sensit
mnt
assay
consequ
weak
correl
baselin
hi
mnt
result
individu
fig
mani
subject
undetect
hi
titr
posit
mnt
titr
suggest
mnt
identifi
subject
despit
neg
hi
nevertheless
seroprotect
level
neutralis
nonhi
antibodi
interestingli
postimmun
much
stronger
posit
correl
hi
mnt
level
subject
fig
suggest
vaccin
induc
similar
proport
hi
mnt
antibodi
advax
adjuv
equal
favor
effect
hi
mnt
respons
mean
fold
increas
hi
mnt
higher
compar
test
abil
induc
broadli
neutralis
antibodi
influenza
strain
hi
mnt
assay
also
perform
histor
strain
apuerto
strain
ahong
x
apuerto
mnt
assay
detect
neutralis
antibodi
target
ha
stem
therebi
neutralis
homolog
heterolog
wherea
hi
assay
detect
neutralis
antibodi
direct
ha
head
henc
specif
homolog
viru
expect
differ
sequenc
ha
head
region
studi
subject
show
increas
hi
heterolog
virus
postimmun
fig
left
side
howev
sensit
mnt
assay
reveal
seroconvers
subject
group
vs
subject
alon
group
fig
right
side
given
lack
detect
hi
subject
suggest
mnt
assay
detect
type
neutralis
antibodi
target
ha
stem
region
ha
stem
antibodi
difficult
induc
interest
futur
confirm
whether
advaxadjuv
rha
abl
induc
broadli
neutralis
stem
antibodi
next
assess
effect
subject
age
antibodi
level
subject
age
effect
baselin
antibodi
respons
subject
older
higher
baselin
titr
viru
fig
suggest
older
subject
like
encount
virus
past
howev
homolog
viru
differ
baselin
titr
age
fig
consist
new
viru
human
previous
expos
interestingli
correl
age
time
immun
foldchang
mnt
fig
contrast
previou
data
show
neg
correl
age
season
influenza
hi
pandem
highlight
need
new
technolog
allow
rapid
design
manufactur
pandem
influenza
vaccin
season
vaccin
base
insectcel
express
rha
time
pandem
still
await
fda
approv
sinc
licens
usa
use
adult
subject
present
rare
opportun
test
novel
rha
vaccin
technolog
context
reallif
pandem
baculoviru
express
technolog
use
produc
extrem
fast
avoid
need
creation
egg
cell
cultur
adapt
influenza
virus
inde
develop
perform
month
initi
viru
identif
first
human
trial
dose
administ
make
potenti
one
fastest
vaccin
develop
program
histori
surprisingli
rha
express
initi
cdc
recommend
refer
sequenc
show
agglutin
activ
uniqu
occurr
one
complex
studi
influenza
virus
variant
limit
receptor
recognit
sever
altern
structur
mechan
exist
adapt
bind
properti
broad
rang
ha
residu
abil
influenc
receptor
bind
furthermor
abil
ha
agglutin
rbc
reli
abil
multimer
specul
anoth
potenti
reason
failur
rha
agglutin
rbc
could
variant
fail
assembl
properli
ha
timer
rosett
need
agglutin
activ
henc
lower
avid
sialic
acid
receptor
also
unabl
crosslink
induc
rbc
agglutin
cdc
subsequ
issu
differ
vaccin
seed
strain
later
use
manufactur
inactiv
vaccin
also
psc
manufactur
rha
inclus
subsequ
year
season
trival
flublok
vaccin
iron
origin
mnufactur
rha
gene
spontan
revert
clone
sequenc
agglutin
activ
follow
procedur
use
season
influenza
vaccin
manufactur
ha
sequenc
mutat
back
cdc
refer
sequenc
agglutin
problem
impos
delay
vaccin
deliveri
requir
mycoplasma
cultur
allow
lot
releas
futur
possibl
use
fdaapprov
pcr
mycoplasma
assay
therebi
remov
week
time
need
vaccin
releas
nevertheless
despit
challeng
panblokadvax
first
vaccin
world
becom
avail
clinic
test
trial
confirm
immunogen
safe
well
toler
interestingli
depend
antigen
use
hi
assay
slightli
differ
estim
obtain
baselin
seroprotect
level
studi
popul
report
studi
result
use
wildtyp
viru
viru
isol
local
patient
pandem
influenza
may
underst
overal
seroprotect
level
report
rel
report
vaccin
furthermor
wherea
mani
pandem
vaccin
studi
includ
mainli
young
healthi
subject
studi
includ
extrem
high
proport
elderli
obes
chronic
diseas
subject
like
neg
impact
overal
seroprotect
level
subject
age
report
elsewher
lower
influenza
vaccin
henc
direct
comparison
difficult
hi
titer
differ
studi
result
highli
depend
assay
antigen
furthermor
seroprotect
rate
measur
hi
assay
like
underst
total
protect
particularli
compar
mnt
assay
mnt
assay
provid
sensit
measur
seroprotect
given
abil
also
detect
antibodi
target
import
viral
epitop
stem
region
involv
viral
mnt
assay
provid
much
higher
estim
baselin
immun
across
studi
popul
mani
subject
neg
hi
seroposit
mnt
assay
advax
adjuv
induc
increas
mnt
tter
vs
higher
titer
hi
assay
hi
assay
detect
vaccin
effect
heterolog
antibodi
viru
strain
sensit
mnt
assay
show
induc
seroconvers
trial
subject
rais
possibl
induc
ha
stem
antibodi
subject
stem
antibodi
confer
broad
crossprotect
heterolog
influenza
virus
import
area
futur
studi
abil
advax
adjuv
induc
broader
crossprotect
respons
seen
anim
studi
formul
inactiv
japanes
enceph
viru
antigen
advax
result
robust
crossprotect
heterolog
flavivirus
includ
murray
valley
enceph
west
nile
enhanc
protect
transferr
immunis
mice
use
memori
b
cell
suggest
advax
enhanc
product
broadli
crossprotect
memori
b
cell
recent
human
influenza
studi
show
subject
receiv
advaxadjuv
inactiv
influenza
vaccin
higher
day
postimmunis
plasmablast
respons
enhanc
express
activationinduc
cytidin
deaminas
translat
greater
antibodi
avid
advax
shown
anim
model
potent
induc
memori
one
import
aspect
abl
address
studi
whether
also
enhanc
human
tcell
immun
influenza
cell
recent
shown
make
import
contribut
human
influenza
futur
studi
need
identifi
whether
better
immun
correl
influenza
protect
found
supplement
replac
inform
provid
hi
assay
merit
ad
adjuv
season
influenza
vaccin
wide
debat
studi
vaccin
demonstr
vital
import
adjuv
high
level
reason
season
vaccin
gener
requir
adjuv
peopl
alreadi
prime
past
season
influenza
infect
relat
strain
furthermor
inactiv
viru
vaccin
contain
contamin
includ
viral
rna
neuraminidas
nuclear
protein
act
inbuilt
inactiv
influenza
vaccin
lose
immunogen
administ
tolllik
receptor
tlr
knockout
mice
therebi
demonstr
import
viral
rna
innat
immun
activ
vaccin
alon
togeth
advax
adjuv
well
toler
common
local
reaction
inject
site
discomfort
local
reaction
bruis
red
swell
local
reaction
low
grade
surprisingli
postimmunis
headach
significantli
lower
subject
receiv
advax
adjuv
compar
alon
suggest
advax
adjuv
suppress
immunis
headach
though
current
unidentifi
adjuv
ultim
essenti
immunogen
vaccin
rare
except
vaccin
highpathogen
avian
influenza
strain
clearli
shown
adjuv
need
adequ
seroprotect
littl
time
avail
vaccin
design
world
face
reallif
pandem
given
except
rate
viru
spread
particular
wetlaboratori
method
studi
new
virus
requir
viru
first
success
cultur
even
risk
viru
mutat
cultur
fulli
repres
wildtyp
virus
caus
pandem
highlight
problem
refer
sequenc
rha
sequenc
agglutin
activ
problem
ultim
solv
repres
strain
caus
time
delay
due
problem
vaccin
manufactur
show
rapid
analysi
new
mutant
influenza
strain
base
silico
structur
model
provid
import
earli
insight
key
viru
properti
includ
abil
bind
human
avian
sialic
acid
receptor
futur
silico
approach
like
becom
routin
analysi
new
pandem
virus
limit
current
studi
includ
inabl
studi
follow
assess
actual
protect
pandem
viru
use
viral
cultur
individu
develop
symptom
influenzalik
ill
howev
detail
initi
studi
report
exposur
pandem
viru
indirectli
assess
look
serolog
evid
boost
antibodi
titr
period
week
post
second
immunis
end
studi
expect
infect
pandem
viru
result
boost
titr
fact
extrem
low
rate
late
seroconvers
week
suggest
subject
protect
peak
period
pandem
pandem
viru
wide
circul
commun
would
also
use
direct
comparison
within
studi
immunogen
advaxadjuv
recombin
hemagglutinin
vaccin
commerci
inactiv
viru
vaccin
possibl
time
studi
commenc
pandem
vaccin
base
inactiv
viru
yet
avail
would
use
crystal
structur
ha
bound
human
avian
sialic
acid
receptor
confirm
predict
silico
structur
model
previous
use
similar
model
approach
predict
structur
behavior
ha
novel
influenza
abl
confirm
accuraci
model
publish
crystal
structur
overal
mani
lesson
learn
pandem
demonstr
need
greater
speed
scalabl
pandem
vaccin
manufactur
reallif
pandem
scenario
prove
recombin
hemagglutinin
vaccin
could
design
manufactur
extrem
quickli
make
ideal
pandem
platform
recombin
baculoviru
stock
ad
bioreactor
contain
sf
cell
incub
hour
infect
cell
remov
bioreactor
separ
cultur
media
centrifug
solubil
use
nonion
deterg
rha
purifi
depth
filtrat
ionexchang
exchang
chromatographi
hydrophob
interact
chromatographi
qmembran
final
ultrafiltr
describ
investig
lot
use
clinic
studi
test
puriti
protein
content
gener
safeti
steril
ph
addit
biochem
biolog
character
monoval
bulk
concentr
includ
conform
assay
sensit
trypsin
digest
ntermin
sequenc
total
amino
acid
analysi
ha
activ
glycosyl
reagent
use
srid
assay
ha
antigen
content
avail
time
formul
initi
lot
formul
base
protein
content
determin
bicinchonin
acid
bca
assay
extract
antigen
fill
vial
respect
although
cgmp
manufactur
complet
midjun
releas
final
product
clinic
trial
delay
need
undertak
mycoplasma
cultur
test
soon
mycoplasma
result
avail
antigen
releas
clinic
trial
commenc
juli
make
first
pandem
vaccin
enter
clinic
test
worldwid
clinic
trial
conduct
random
subject
observerblind
parallel
group
trial
group
receiv
one
rha
dose
alon
formul
advax
delta
inulin
trial
includ
adult
exclus
includ
pregnanc
immunosuppress
therapi
oral
corticosteroid
hiv
infect
histori
drug
alcohol
abus
howev
unlik
mani
studi
exclus
made
base
older
age
presenc
chronic
diseas
two
immunis
administ
intramuscularli
week
apart
antibodi
respons
measur
week
immunis
first
man
studi
assess
vaccin
safeti
major
prioriti
solicit
local
system
reaction
collect
memori
aid
seriou
advers
event
collect
throughout
studi
period
previous
report
subject
enrol
random
baselin
serolog
receiv
first
vaccin
dose
subject
predominantli
caucasian
median
age
seventi
percent
subject
overweight
obes
medic
one
chronic
diseas
mani
trial
subject
belong
highrisk
group
recommend
season
influenza
vaccin
alreadi
receiv
season
trival
influenza
vaccin
antibodi
titr
determin
hi
assay
pair
serum
run
simultan
assay
briefli
serum
pretreat
volum
receptor
destroy
enzym
denka
seiken
tokyo
japan
enzym
inactiv
min
sampl
mix
part
guinea
pig
red
blood
cell
grbc
remov
nonspecif
agglutinin
inhibitor
haemagglutinin
grbc
pellet
brief
centrifug
sera
mix
part
pb
obtain
vv
dilut
sampl
hi
assay
perform
grbc
follow
manual
anim
influenza
diagnosi
surveil
pretreat
sera
incub
ha
unit
relev
ha
antigen
hour
room
temperatur
addit
grbc
cell
suspens
plate
incub
hour
room
temperatur
read
hi
titr
express
reciproc
final
serum
dilut
complet
inhibit
haemagglutin
endpoint
seroprotect
defin
hai
titer
seroconvers
increas
titer
hai
titer
fold
increas
geometr
mean
titer
gmt
geometr
mean
confid
interv
pvalu
determin
pre
post
patient
serum
hai
data
set
use
graphpad
prism
graphpad
softwar
inc
san
diego
california
usa
mnt
assay
perform
step
virusantibodi
reaction
step
viru
mix
antibodi
present
sampl
inocul
step
madindarbi
canin
kidney
mdck
cell
ad
cultur
plate
incub
overnight
everi
plate
includ
standard
antibodi
correspond
test
viru
check
assay
done
properli
medium
use
dilut
dmem
supplement
fb
tpcktrypsin
work
dilut
viru
determin
viru
titrat
use
mdck
cell
experi
fresh
aliquot
viru
use
firstli
serial
dilut
sampl
viru
mix
plate
incub
hour
halflogarithm
dilut
step
chosen
broad
rang
serum
dilut
standard
antibodi
midrang
titer
includ
posit
control
mdck
cell
ad
well
incub
done
overnight
remov
media
plate
wash
pb
fix
fix
meohaceton
per
well
minut
follow
immunostain
step
detect
amount
influenza
viral
nucleoprotein
hundr
per
well
mous
antiinfluenza
viru
nucleoprotein
antibodi
bei
dilut
bsapb
ad
incub
hour
room
temperatur
wash
per
well
detect
biotinantimous
bsapb
antibodi
plu
streptavidinhrp
ad
incub
hour
wash
per
well
dab
substrat
ad
incub
minut
allow
color
develop
plate
wash
thoroughli
tap
water
dri
invert
overnight
scan
count
use
imag
analyz
version
cellular
technolog
ltd
cleveland
oh
adapt
microneutralis
viru
titrat
microneutralis
give
result
end
point
titer
express
reciproc
highest
dilut
serum
infect
cell
number
less
x
x
half
differ
averag
number
infect
cell
posit
control
well
averag
number
infect
cell
neg
control
well
well
sever
infect
cell
x
valu
consid
posit
neutralis
absenc
infect
indic
presenc
virusspecif
antibodi
sampl
enough
amount
prevent
influenza
viru
infect
cell
decreas
variabl
result
microneutralis
duplic
sampl
replic
assay
combin
geometr
mean
give
singl
titer
calcul
neg
mnt
titer
assign
valu
half
minimum
detect
titr
greater
final
dilut
assign
valu
twice
maximum
detect
ha
model
global
align
ucsf
chimera
softwar
version
use
align
clustalo
program
uniprot
websit
http
wwwuniprotorg
also
use
precis
accur
align
molecular
dock
sialic
acid
receptor
perform
use
molecular
dock
program
autodock
vina
version
prepar
ligand
receptor
dock
calcul
conduct
use
program
autodock
tool
adt
firstli
polar
hydrogen
ad
receptor
follow
assign
kollman
unit
atom
partial
charg
search
space
angstrom
defin
within
receptor
bind
pocket
ha
molecul
autodock
atom
type
assign
ligand
molecul
follow
assign
kollman
unit
atom
partial
charg
torsion
angl
ligand
set
free
allow
flexibl
dock
exhaust
use
search
final
possibl
bind
mode
calcul
compar
structur
sequenc
differ
hemagglutinin
ha
refer
structur
rcsb
protein
data
bank
pdb
http
wwwrcsborgpdb
use
ha
viru
ha
viru
ha
close
relationship
ha
viru
